The observed synergy of ibrutinib and immune checkpoint inhibition is in line with the work of Sagiv-Barfi et al., where the combination of ibrutinib with anti-PD-L1 agents proved efficient even in tumors (lymphomas) intrinsically insensitive to ibrutinib, with an approx. 50% cure rate in mice. Here, CD274 is linked to lymphoma.